Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

2012 Annual Meeting | Clinical Issues in Multiple Sclerosis

Friday 04/27/12
08:00 AM - 12:00 PM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
AM Half-Day Course
Brian G. Weinshenker, MD, FÂ鶹´«Ã½Ó³»­
Participants will have an enhanced perspective on the role of MRI in MS clinical trials, clinical potential for stratification of MS treatment based on immunological discoveries, cost-effectiveness of MS treatments, and symptomatic treatment of MS-related disabilities with dalfampridine. Participants will have enhanced understanding of diagnostic and therapeutic strategies for common and unusual CNS demyelinating disease.
No CME available
Patient Care & Procedural Skills, Medical Knowledge
Other, Trainee, General Neurologist, Specialist Neurologist
Case-based, Didactic, Interactive, Audience Participation, Other

Program Evaluations

Event Timeline
08:00 AM - 08:15 AM Debate #1: Resolved That MRI is a Suitable Endpoint for Phase III MS Trials for Relapsing-Remitting MS, Replacing Attacks/Disability: Affirmative Argument
Dean M. Wingerchuk, MD, FÂ鶹´«Ã½Ó³»­
08:15 AM - 08:30 AM Debate #1: Resolved That MRI is a Suitable Endpoint for Phase III MS Trials for Relapsing-Remitting MS, Replacing Attacks/Disability: Negative Argument
Alex D. Rae-Grant, MD, FRCPC, FÂ鶹´«Ã½Ó³»­
08:30 AM - 08:50 AM Debate #1: Rebuttals and Summary
08:50 AM - 09:05 AM Cost-effectiveness: Is It an Informative Way to Assess the Clinical Value of Disease-Modifying Treatments in MS?
Dean M. Wingerchuk, MD, FÂ鶹´«Ã½Ó³»­
09:05 AM - 09:20 AM Debate #2: Resolved that MS Treatments Vary in Effectiveness Based On Whether the Immune System Is Th1 or Th17 Polarized: Affirmative Argument
Brian G. Weinshenker, MD, FÂ鶹´«Ã½Ó³»­
09:20 AM - 09:35 AM Debate #2: Resolved that MS Treatments Vary in Effectiveness Based On Whether the Immune System Is Th1 or Th17 Polarized: Negative Argument
Alasdair Coles, MD, PhD
09:35 AM - 09:55 AM Debate #2: Rebuttals and Summary
09:55 AM - 10:10 AM Break
10:10 AM - 10:25 AM Dalfampridine: How Valuable Is It for Treatment of Patients with MS-related Impairment?
Alex D. Rae-Grant, MD, FRCPC, FÂ鶹´«Ã½Ó³»­
10:25 AM - 10:40 AM B-cells vs T-cells in MS: Are B-cell Directed Treatments as Good as T-cell Directed? Are They Better for Some Patients than for Others?
Alasdair Coles, MD, PhD
10:40 AM - 12:00 PM Interactive Case Discussions: Diagnostic Difficulties, Early Management Controversies and Treatment of Refractory Cases
Brian G. Weinshenker, MD, FÂ鶹´«Ã½Ó³»­, Dean M. Wingerchuk, MD, FÂ鶹´«Ã½Ó³»­
Faculty Disclosures
Brian G. Weinshenker, MD, FÂ鶹´«Ã½Ó³»­ Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharmaceuticals. Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zenas Pharma. Dr. Weinshenker has received research support from Guthy Jackson Charitable Foundation. Dr. Weinshenker has received intellectual property interests from a discovery or technology relating to health care.
Dean M. Wingerchuk, MD, FÂ鶹´«Ã½Ó³»­ Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Meyer Squibb. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wolters Kluwers.
Alex D. Rae-Grant, MD, FRCPC, FÂ鶹´«Ã½Ó³»­ Dr. Rae-Grant has received publishing royalties from a publication relating to health care. Dr. Rae-Grant has received publishing royalties from a publication relating to health care.
Alasdair Coles, MD, PhD Dr. Coles has nothing to disclose.